AbbVie Inc. has announced a $380 million investment to expand its U.S. manufacturing capabilities with the construction of two new active pharmaceutical ingredient facilities in North Chicago. This strategic move comes despite a recent downgrade from RBC Capital Markets, shifting its rating from 'Strong' to 'Neutral.' Additionally, AbbVie received FDA approval for a new leukemia treatment, bolstering its oncology portfolio as it pursues a $20 billion acquisition of Revolution Medicines. Despite a 13.6% rise over the past year, concerns linger over stock performance fluctuations and an impending EPS forecast of $3.01.
“RBC Capital Markets · has initiated · coverage of AbbVie · at Outperform”
“ABBV AbbVie, Inc. · was downgraded · from Strong to Neutral · B C C”
“AbbVie · received · FDA approval · first in class, all oral, fixed duration regimen combining VENCLEXTA and acalabrutinib for previously untreated chronic lymphocytic leukemia”
“AbbVie · announced · investment · $380 million in advanced U.S. manufacturing facilities in North Chicago”
“RBC Capital Markets · has initiated coverage of · ABBVIE · at Outperform”
“RBC Capital analyst Trung Huynh · initiated coverage of · AbbVie Inc. (NYSE:ABBV) · Outperform rating and a $260 price target”
“AbbVie · plans to invest · $380 million · to build two new active pharmaceutical ingredient manufacturing facilities”
“AbbVie · expects to hire · about 300 employees · at the site”
“AbbVie · is part of a plan to spend · $100 billion · on US research and manufacturing over the next decade”
“AbbVie · is rated · Outperform · true”
“AbbVie · has a price target of · $260 · true”
“AbbVie Inc. · was initiated with · an Outperform rating · at RBC Capital”
